Assyro AI

FDA Orange Book · active-ingredient family

Captopril

Captopril is approved as 1 brand and 26 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:CAPOTEN · NDA 018343

1

Brand (NDA)

26

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
CAPOTENRLD×7AARXION ANDA HLDINGNDA 018343Jan 17, 1985

Generic (ANDA) products (26)

ProductApplicantApplicationTEApproved
CAPTOPRIL×4AIPING PHARM INCANDA 214442ABJan 27, 2023
CAPTOPRIL×4AJANTA PHARMA LTDANDA 212809ABDec 13, 2019
CAPTOPRIL×4SETON PHARMSANDA 212223Oct 30, 2019
CAPTOPRIL×4COREPHARMAANDA 074737ABOct 28, 1998
CAPTOPRIL×4ANDAS 5 HOLDINGANDA 074677ABMay 30, 1997
CAPTOPRIL×4EGIS PHARMSANDA 074748May 29, 1997
CAPTOPRIL×4PUREPAC PHARMANDA 074640Mar 31, 1997
CAPTOPRIL×4WOCKHARDT BIO AGANDA 074532ABMar 28, 1997
CAPTOPRIL×4G AND W LABS INCANDA 074590Aug 30, 1996
CAPTOPRIL×4WATSON LABSANDA 074386May 23, 1996
CAPTOPRIL×4WATSON LABSANDA 074576Apr 23, 1996
CAPTOPRIL×4AUROBINDO PHARMA USAANDA 074434Feb 13, 1996
CAPTOPRIL×4CHARTWELL RXANDA 074519Feb 13, 1996
CAPTOPRIL×4COSETTE PHARMS NCANDA 074433Feb 13, 1996
CAPTOPRIL×4COSETTE PHARMS NCANDA 074462Feb 13, 1996
CAPTOPRIL×4COSETTE PHARMS NCANDA 074483Feb 13, 1996
CAPTOPRIL×4DAVA PHARMS INCANDA 074423Feb 13, 1996
CAPTOPRIL×4HIKMA INTL PHARMSANDA 074505ABFeb 13, 1996
CAPTOPRIL×4OXFORD PHARMSANDA 074418Feb 13, 1996
CAPTOPRIL×4PRINSTON INCANDA 074477ABFeb 13, 1996
CAPTOPRIL×4SANDOZANDA 074481Feb 13, 1996
CAPTOPRIL×4STRIDES PHARMA INTLANDA 074493Feb 13, 1996
CAPTOPRIL×4TEVAANDA 074322Feb 13, 1996
CAPTOPRIL×4WATSON LABSANDA 074451Feb 13, 1996
CAPTOPRIL×4CHARTWELL RXANDA 074363Nov 09, 1995
CAPTOPRIL×4APOTHECONANDA 074472Mar 31, 1995

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Captopril — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.